Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Hypophosphatasia (HPP) is a genetic enzyme disorder in which low alkaline phosphatase activity blocks bone mineralization, so weak bones in HPP are not caused by a lack of calcium or vitamin D, and routine supplementation can be actively harmful. Because many people with HPP already run high blood or urine calcium levels, added calcium and high-dose vitamin D can drive hypercalcemia, hypercalciuria, kidney stones, nephrocalcinosis, and lasting kidney damage, while doing nothing to correct the underlying enzyme defect. Important exceptions exist, including docum
Hypophosphatasia (HPP) is a rare genetic bone disorder caused by mutations in the ALPL gene, which leads to deficient tissue-nonspecific alkaline phosphatase (TNSALP) activity. As a result, mineralization of bone and teeth is impaired. While calcium and vitamin D supplements are commonly used to support bone health, in HPP patients they can do more harm than good. Read on to learn about the calcium and vitamin D supplements danger in HPP, and what you can do to stay safe.
Vitamin D
Calcium
Standard use
In HPP, low TNSALP fails to break down PPi, a powerful inhibitor of hydroxyapatite crystal formation (the mineral core of bone). Adding more calcium or vitamin D doesn’t correct this defect—in fact, it leads to:
These issues arise because the body can’t deposit the extra calcium into bones as intended. Instead, calcium lingers in the blood, is filtered by the kidneys, and ends up in places where it doesn’t belong.
Kidney Damage
Soft-Tissue Calcification
Worsening Bone Disease
Electrolyte Imbalance
If you have HPP and you’re taking calcium or vitamin D supplements, watch for:
These could be signs of hypercalcemia or nephrocalcinosis—both require immediate medical attention.
Because standard bone-support regimens can be harmful, HPP patients need a tailored approach:
• Confirm diagnosis with genetic testing and measure serum alkaline phosphatase.
• Avoid routine calcium and vitamin D supplementation unless a clear deficiency is documented.
• Use enzyme replacement therapy (asfotase alfa), which directly addresses low TNSALP.
• Monitor calcium, phosphate, PLP and urinary calcium levels regularly.
• Consult a metabolic bone specialist or geneticist for ongoing care.
• Consider physical therapy, safe exercise and pain-control strategies.
Nutrition and lifestyle modifications should focus on a balanced diet, adequate—but not excessive—vitamin D from food or limited sun exposure, and careful monitoring of blood and urine tests.
Disclaimer: This information is not a substitute for professional medical advice. If you suspect life‐threatening complications or serious problems, please speak to a doctor immediately.
(References)
* Rubinstein HM, Shah DM. Pseudogout. Semin Arthritis Rheum. 1972-1973;2(3):259-80. doi: 10.1016/0049-0172(72)90011-x. PMID: 4354552.
* Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Dahir KM, Nunes ME. Hypophosphatasia. 1993. PMID: 20301329.
* Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Lewiecki EM. Osteoporosis: Clinical Evaluation. 2000. PMID: 25905277.
* Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Marini JC, Dang Do AN. Osteogenesis Imperfecta. 2000. PMID: 25905334.
* Linglart A, Biosse-Duplan M. Hypophosphatasia. Curr Osteoporos Rep. 2016 Jun;14(3):95-105. doi: 10.1007/s11914-016-0309-0. PMID: 27084188.
* Kishnani PS, Rush ET, Arundel P, Bishop N, Dahir K, Fraser W, Harmatz P, Linglart A, Munns CF, Nunes ME, Saal HM, Seefried L, Ozono K. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Mol Genet Metab. 2017 Sep;122(1-2):4-17. doi: 10.1016/j.ymgme.2017.07.010. Epub 2017 Jul 25. PMID: 28888853.
* Cormier C. Genetic hypercalcemia. Joint Bone Spine. 2019 Jul;86(4):459-466. doi: 10.1016/j.jbspin.2018.10.001. Epub 2018 Oct 6. PMID: 30300686.
* Fenn JS, Lorde N, Ward JM, Borovickova I. Hypophosphatasia. J Clin Pathol. 2021 Oct;74(10):635-640. doi: 10.1136/jclinpath-2021-207426. Epub 2021 Apr 30. PMID: 33931563.
* Cianferotti L. Osteomalacia Is Not a Single Disease. Int J Mol Sci. 2022 Nov 28;23(23). doi: 10.3390/ijms232314896. Epub 2022 Nov 28. PMID: 36499221; PMCID: PMC9740398.
* Pascart T, Filippou G, Lioté F, Sirotti S, Jauffret C, Abhishek A. Calcium pyrophosphate deposition disease. Lancet Rheumatol. 2024 Nov;6(11):e791-e804. doi: 10.1016/S2665-9913(24)00122-X. Epub 2024 Jul 29. PMID: 39089298.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.